Mustang Bio, Inc. (MBIO) stock
Close on Nov 18, 2026Market cap $2.88MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.88M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.03M
- EPS, diluted
- -$0.45
- Book value per share
- $1.12
- Diluted shares
- 7M
Trading
- Previous close
- $0.39
- Open
- $0.39
- Day's range
- $0.38 – $0.40
- Volume
- 9,840
- Average volume (20 days)
- 34,643
- 52-week range
- $0.35 – $1.43
- RSI (14 days)
- 42.6
- Volatility (1 year)
- 67.6%
- Relative volume
- 0.30×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | MBIO | S&P 500 | Difference | MBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.0% | -4.3% | +5.3 pts | ||
| 3 months | -33.3% | -4.6% | −28.7 pts | ||
| Year to date | -61.3% | +7.9% | −69.2 pts | ||
| 1 year | -69.1% | +11.8% | −80.9 pts | ||
| 3 years | -99.5% | +68.0% | −167.5 pts | -83.3% | +18.9% |
| 5 years | -100.0% | +66.2% | −166.2 pts | -81.3% | +10.7% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Mustang Bio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Mustang Bio
Pharmaceutical Preparations
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on acquiring, developing, and commercializing novel cancer therapies, specifically targeting difficult-to-treat solid tumors. Operating as a majority-controlled subsidiary of Fortress Biotech, Inc., the company concentrates on cell and viral immunotherapies. Its principal pipeline assets include MB-101, an engineered CAR T-cell therapy directed at IL13Rα2, and MB-108, an oncolytic herpes simplex virus. Mustang is also investigating MB-109, a combination regimen evaluating MB-101 and MB-108 for the treatment of malignant brain tumors, including recurrent glioblastoma and high-grade astrocytoma. Because its product candidates remain in clinical evaluation and have not received regulatory marketing approval, the company does not currently serve commercial patients or end-user customers.
Company profile, executives and historyMustang Bio stock: common questions
What is Mustang Bio's stock price?
MBIO closed at $0.38 on Nov 18, 2026, down 2.56% on the day. Over the past 52 weeks it traded between $0.35 and $1.43.
What is Mustang Bio's market cap?
Mustang Bio was worth $2.88M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is MBIO's P/E ratio?
Mustang Bio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.45), so it has no meaningful P/E ratio.
Does Mustang Bio pay a dividend?
No. Mustang Bio has not paid a cash dividend over the last twelve months.
How has MBIO stock performed over the past year?
Including dividends, MBIO returned -69.1% over the past year, against +11.8% for the S&P 500.
How many MBIO shares are sold short?
0M shares were sold short at the latest FINRA report, 1.00% of the float, or 2.8 days of average trading volume.
Who are Mustang Bio's competitors?
Companies most similar to Mustang Bio by business, industry and size include CRBP, NTHI, GTBP, PYXS, NWBO.
See a number that looks wrong?